PMID- 23271459
OWN - NLM
STAT- MEDLINE
DCOM- 20130704
LR  - 20220331
IS  - 1573-2592 (Electronic)
IS  - 0271-9142 (Linking)
VI  - 33 Suppl 2
DP  - 2013 Jan
TI  - Using intravenous immunoglobulin (IVIG) to treat patients with primary immune 
      deficiency disease.
PG  - S90-4
LID - 10.1007/s10875-012-9838-1 [doi]
AB  - The treatment of primary immunodeficiency disease (PIDD) patients with 
      immunoglobulin obtained from healthy controls, given intravenously, is a 
      relatively recent event, having first been given in 1981. Intravenous 
      immunoglobulin (IVIG) replacement in PIDD has been shown to prevent 
      serious/recurrent infections because higher IgG levels can be obtained through IV 
      administration, as opposed to the intramuscular route. Significant variation in 
      IgG levels in controls is dependent on age and sex, which provides the rationale 
      for the concept that there is a "biological IgG trough/level", hereafter called 
      biological IgG level, in PIDD, as there is in healthy controls. Each PIDD patient 
      has a biological IgG level that can be altered by comorbid conditions that evoke 
      IgG loss or changes in metabolism/catabolism. The pharmacokinetic comparison of 
      IVIG vs. SCIG demonstrates the various benefits of each in treating PIDD. Acutely 
      ill PIDD patients should only receive IVIG. "Rush" SCIG treatment can also be 
      used to attain the biological IgG level, but for less emergent care of PIDD. 
      Finally, future opportunities exist to enhance IgG replacement in PIDD, including 
      microbe-specific IgG and IgG subclass-specific enriched preparations.
FAU - Bonagura, Vincent R
AU  - Bonagura VR
AD  - Steven and Alexandra Cohen Children's Medical Center of New York, North 
      Shore-Long Island Jewish Health System, 865 Northern Blvd, Suite 101, Great Neck, 
      NY 11021, USA. vbonagura@nshs.edu
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121228
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/pharmacokinetics/*therapeutic use
MH  - Immunologic Deficiency Syndromes/immunology/*therapy
MH  - Immunotherapy/*methods
MH  - Infection Control
MH  - Infections/etiology
MH  - Precision Medicine
MH  - Treatment Outcome
EDAT- 2012/12/29 06:00
MHDA- 2013/07/05 06:00
CRDT- 2012/12/29 06:00
PHST- 2012/08/16 00:00 [received]
PHST- 2012/11/12 00:00 [accepted]
PHST- 2012/12/29 06:00 [entrez]
PHST- 2012/12/29 06:00 [pubmed]
PHST- 2013/07/05 06:00 [medline]
AID - 10.1007/s10875-012-9838-1 [doi]
PST - ppublish
SO  - J Clin Immunol. 2013 Jan;33 Suppl 2:S90-4. doi: 10.1007/s10875-012-9838-1. Epub 
      2012 Dec 28.